

SAMPRE NUTRITIONS LIMITED



CIN: L15499TG1991PLC013515

29.07.2017

To
The Corporate Relationship Department
BSE Limited
P J Towers, Dalal Street
Fort, **MUMBAI**

Dear Sir,

Sub: Submission of the Un-audited Financial Results & Limited Review Report for the First Quarter and Three Months ended 30th June, 2017– Reg.

Ref: Script Code: 530617

With reference to above cited subject, Board of Directors in their just concluded Board Meeting has considered and adopted Un-audited Financial Results for the First Quarter and three months ended 30th June, 2017.

Further Limited Review Report for the Quarter ended 30.06.2017 is also enclosed herewith in compliance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you.

Yours Truly,
For **SAMPRE NUTRITIONS LIMITED**


B K GURBANI
Chairman & Managing Director



Encl: As above

Regd. Off & Works : Unit-1 : Plot No.133, I.E, Medchal - 501 401. Telangana, India.
Unit-2 : Plot No. 127,128, Royes Building, I.E, Medchal, R.R.Dist - 501 401. Telangana.
Ph : +91-8418-222428, 222429, Fax : +91-8418-222427
e-mail : gurbani@gurbanigroup.in, bkgurbani@gurbanigroup.in, www.gurbanigroup.com



**LIMITED REVIEW REPORT ON THE UN-AUDITED FINANCIAL RESULTS OF
SAMPRE NUTRITIONS LIMITED, PURSUANT TO THE REQUIREMENTS OF
REGULATION 33 OF THE SEBI (LISTING, OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015.**

To
Board of Directors of **Sampre Nutritions Limited**
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **Sampre Nutritions Limited** for the period ended 30/06/2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RRK & Associates
Chartered Accountants
FRN009785S

R.Radha Krishna
Partner
M.No.210777



Date: 29.07.2017
Place: Hyderabad

SAMPRE NUTRITIONS LIMITED

CIN: L15499TG1991PLC013515

Statement of Un-audited Financial Results for the First Quarter and 3 Months Ended 30th June, 2017

S.NO.	Particulars	₹ (In Lakhs)			
		Quarter ended		Year ended	
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		Un-Audited	Audited	Un-Audited	Audited
I	Revenue from operations	909.03	754.89	1262.80	3358.16
II	Other income	21.12	3.85	1.34	8.18
III	Total Revenue (I + II)	930.15	758.74	1264.14	3366.34
IV	Expenses:				
	Cost of materials consumed	548.32	426.34	876.10	2136.93
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	0.00	0.00	0.00	0
	Employee benefits expense	25.43	28.35	16.75	58.74
	Finance Costs	26.38	31.32	20.35	110.81
	Depreciation and amortization expense	42.17	28.65	38.38	128.69
	Direct Manufacturing Expenses	179.68	166.94	264.57	709.68
	Administrative Expenses	74.52	53.02	35.25	155.23
	Other expenses	0.00	0.00	0	0
	Total expenses (IV)	896.50	734.62	1251.40	3300.08
V	Profit before exceptional items and tax (III - IV)	33.65	24.12	12.74	66.26
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit before tax (V- VI)	33.65	24.12	12.74	66.26
VIII	Tax expense:				
	(1) Current tax	13.46	14.65	0.00	26.65
	(2) Deferred tax	0.00	0.00	0.00	-5.56
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	20.19	9.47	12.74	45.17
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax) (X-XI)	0.00	0.00	0.00	0.00
XIII	Profit (Loss) for the period (IX + XII)	20.19	9.47	12.74	45.17
XIV	Other Comprehensive Income				
	A (i). Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i). Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii). Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII+XIV)	20.19	9.47	12.74	45.17
XVI	Earnings per equity share: (for continuing operations)				
	(1) Basic	0.42	0.20	0.26	0.94
	(2) Diluted	0.42	0.20	0.26	0.94
XVII	Earnings per equity share: (for discontinuing operations)				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share: (for continuing & discontinuing operations)				
	(1) Basic	0.42	0.20	0.26	0.94
	(2) Diluted	0.42	0.20	0.26	0.94

NOTES:

- The above standalone un-audited financial results for the quarter ended on June, 30, 2017 as reviewed by Audit Committee were taken on record at the meeting of Board of Directors held on 29th July, 2017.
- During the Quarter Company has entered into manufacturing contract with M/s Patanjali Ayurved Limited and company has started dispatch of products pursuant to the said agreement during quarter. Management is confident of clocking turnover of around Rs. 1200 Lakhs during the F Y 2018-19.
- Company operates in one segment only, so reporting of segmental revenue is not applicable
- The previous period figures are re-grouped, wherever necessary

Date: 29.07.2017
Place: Medchal



For SAMPRE NUTRITIONS LIMITED

B K GURBANI
Chairman & Managing Director